ARTICLE | Clinical News
NovoNorm repaglinide regulatory update
December 8, 2014 8:00 AM UTC
Japan approved an expanded label for Type II diabetes drug Surepost repaglinide to include combination therapy with oral hypoglycemic agents, excluding sulfonylurea and insulin formulations. Sumitomo ...